ArticleFrontiers in oncology2023

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma.

Tomoyuki Satake et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.